Sugi Predict

Sugi Predict / Compounds / SCHEMBL39086

SCHEMBL39086

SCHEMBL39086

Cc1cc(C[C@H](N)C(=O)O)cc(C)c1O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SIRT5 Q9NXA8 1/20 0.58
▸ THRB P10828 7/20 0.55
▸ THRA P10827 5/20 0.55
▸ SLC7A5 Q01650 4/20 0.55
▸ HSD17B10 Q99714 4/20 0.54
▸ USP2 O75604 4/20 0.54
▸ ADORA3 P0DMS8 3/20 0.54
▸ ALOX15 P16050 3/20 0.54
▸ PTGS2 P35354 2/20 0.54
▸ PTGS1 P23219 2/20 0.54
▸ KDM4E B2RXH2 2/20 0.54
▸ RECQL P46063 2/20 0.54
▸ HIF1A Q16665 2/20 0.54
▸ TDP1 Q9NUW8 2/20 0.54
▸ EGFR P00533 1/20 0.54
▸ LCK P06239 1/20 0.54
▸ FYN P06241 1/20 0.54
▸ HTR2A P28223 1/20 0.54
▸ MEN1 O00255 5/20 0.54
▸ KMT2A Q03164 5/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12209352 1.00 SIRT5 (0.58) SIRT5THRBTHRASLC7A5HSD17B10
SCHEMBL25180570 0.91 SLC7A5 (0.58) SIRT5THRBTHRASLC7A5HSD17B10
SCHEMBL13957567 0.91 SLC7A5 (0.58) SIRT5THRBTHRASLC7A5HSD17B10
SCHEMBL20683113 0.90 SIRT5 (0.73) SIRT5THRBTHRAHSD17B10USP2
SCHEMBL19004799 0.90 SIRT5 (0.73) SIRT5THRBTHRAHSD17B10USP2
SCHEMBL3523032 0.89 SIRT5 (0.51) SIRT5THRBTHRASLC7A5HSD17B10
SCHEMBL3523029 0.89 SIRT5 (0.51) SIRT5THRBTHRASLC7A5HSD17B10
SCHEMBL26378959 0.89 SIRT5 (0.51) SIRT5THRBTHRASLC7A5HSD17B10
SCHEMBL19113631 0.88 THRB (0.65) SIRT5THRBTHRASLC7A5HSD17B10
SCHEMBL6825058 0.88 THRB (0.65) SIRT5THRBTHRASLC7A5HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 418 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025044786-A1 PEPTIDES, DERIVATIVES THEREOF, AND USE OF SAME 南京医科大学 2025-03-06 — — WO claimed
CN-117384253-A Peptide, derivative and application thereof 南京医科大学 2024-01-12 — — CN claimed
WO-2023182469-A1 METHOD FOR PRODUCING METHYL PHENOL 三菱ケミカル株式会社 2023-09-28 — — WO claimed
EP-2662079-A1 Uses of formulations of thyroid hormone antagonists and nanoparticulate forms thereof to increase chemosensivity and radiosensitivity in tumor or cancer cells Ordway Research Institute, Inc. (US) 2013-11-13 — — EP claimed
US-20120315320-A1 USES OF FORMULATIONS OF THYROID HORMONE ANALOGS AND NANOPARTICULATE FORMS THEREOF TO INCREASE CHEMOSENSIVITY AND RADIOSENSITIVITY IN TUMOR OR CANCER CELLS NANOPHARMACEUTICALS LLC 2012-12-13 — — US claimed
US-20260125722-A1 METHOD FOR PRODUCING METHYL COMPOUND MITSUBISHI CHEMICAL CORPORATION (JP) 2026-05-07 — — US disclosed
EP-4692363-A1 METHOD FOR PRODUCING METHYL COMPOUND Mitsubishi Chemical Corporation (JP) 2026-02-11 — — EP disclosed
EP-4692361-A1 METHOD FOR PRODUCING METHYL COMPOUND Mitsubishi Chemical Corporation (JP) 2026-02-11 — — EP disclosed
WO-2025079064-A1 INTERLEUKIN-17 PEPTIDOMIMETIC INHIBITORS PEPTICOM LTD. (IL) 2025-04-17 — — WO disclosed
WO-2025044786-A1 PEPTIDES, DERIVATIVES THEREOF, AND USE OF SAME 南京医科大学 2025-03-06 — — WO disclosed
WO-2024204791-A1 METHOD FOR PRODUCING METHYL COMPOUND 三菱ケミカル株式会社 2024-10-03 — — WO disclosed
WO-2024204792-A1 METHOD FOR PRODUCING METHYL COMPOUND 三菱ケミカル株式会社 2024-10-03 — — WO disclosed
US-20070027087-A1 METHODS FOR PREVENTING MITOCHONDRIAL PERMEABILITY TRANSITION NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2007-02-01 — — US disclosed
EP-1722807-A2 METHODS FOR REDUCING OXIDATIVE DAMAGE Cornell Research Foundation Inc. (US) 2006-11-22 — — EP disclosed
CN-1787831-A Method for preventing mitochondrial permeability transition CORNELL RES FOUNDATION INC (US) 2006-06-14 — — CN disclosed
US-20060084606-A1 administering aromatic cationic peptide for specifically target mitochondria; ischemia is due to stroke, sepsis, inflammatory process, arthritis, diabetes, liver disorders, viral infection, to a removed organ CORNELL RESEARCH FOUNDATION, INC. 2006-04-20 — — US disclosed
EP-1599216-A2 METHODS FOR PREVENTING MITOCHONDRIAL PERMEABILITY TRANSITION CORNELL RESEARCH FOUNDATION, INC. (US) 2005-11-30 — — EP disclosed
WO-2005072295-A2 METHODS FOR REDUCING OXIDATIVE DAMAGE CORNELL RESEARCH FOUNDATION, INC. (US) 2005-08-11 — — WO disclosed
US-20040248808-A1 Methods for preventing mitochondrial permeability transition PUBLIC HEALTH SERVICE/NATIONAL INSTITUTES OF HEALTH (NIH) 2004-12-09 — — US disclosed
WO-2004070054-A2 METHODS FOR PREVENTING MITOCHONDRIAL PERMEABILITY TRANSITION CORNELL RESEARCH FOUNDATION, INC. (US) 2004-08-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125722-A1 METHOD FOR PRODUCING METHYL COMPOUND GNMT, MTR, BHMT SIRT5 2584/4885THRB 2934/4885THRA 2691/4885
US-20120315320-A1 USES OF FORMULATIONS OF THYROID HORMONE ANALOGS AND NANOPARTICULATE FORMS THEREOF TO INCREASE CHEMOSENSIVITY AND RADIOSENSITIVITY IN TUMOR OR CANCER CELLS TSHR, TPO, THRA SIRT5 772/4885THRB 5/4885THRA 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback